Nathan Elie Frenk

Nathan Elie Frenk

Auto-generated profile, based on publicly available information

Nathan Elie Frenk

Department of Radiology, Tufts Medical Center, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in American Journal of Roentgenology
Verified
Journal Article
Closed access
NFNathan E. Frenk
Nathan E. Frenk
RBRonaldo H. Baroni
Ronaldo H. Baroni
FCFrancisco C. Carnevale
Francisco C. Carnevale
OGOctavio M. G. Gonçalves
Octavio M. G. Gonçalves
AAAlberto A. Antunes
Alberto A. Antunes
GCGiovanni G. Cerri
Giovanni G. Cerri
The purpose of this article is to assess and describe the MRI findings after prostatic artery embolization for treatment of benign prostatic hyperplasia. We retrospectively evaluated 17 patients who underwent prostatic artery embolization as part of different prospective studies to evaluate this alternative treatment of benign prostatic hyperplasia. Clinical results were evaluated by assessment of urinary catheterization and International Prostate Symptom Score (IPSS). Serial MRI examinations were performed, and the prostatic central gland and peripheral zone were evaluated for signal intensity changes and the presence and characteristics of infarcted areas. Statistical analysis was performed with ANOVA for repeated measures and Student t test. All patients had clinical success, as defined by the removal of indwelling urinary catheter or decreased IPSS after embolization. Infarcts were seen in 70.6% of the subjects, exclusively in the central gland, were almost always characterized by hyperintensity on T1-weighted images and predominant hypointensity on T2-weighted images, and became smaller (mean reduction, p < 0.001) and isointense to the remaining of the central gland over time. Volume reduction of the prostate after embolization was significant (averaging 32.0% after 12-18 months; p < 0.001) only in patients with infarcts. No statistically significant association was seen between the development of infarcts and IPSS. MRI can be used for assessing the development of infarcts and volume reduction in the prostate after embolization. Further studies are needed to correlate these findings to clinical outcome.

1 February 2018 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
NFNathan E. Frenk
Nathan E. Frenk
DDDania Daye
Dania Daye
KTKemal Tuncali
Kemal Tuncali
RARonald S. Arellano
Ronald S. Arellano
PSPaul B. Shyn
Paul B. Shyn
RURaul N. Uppot
Raul N. Uppot

1 November 2017 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
HVHarshna V. Vadvala
Harshna V. Vadvala
VFVanessa Fiorini Furtado
Vanessa Fiorini Furtado
AKAvinash Kambadakone
Avinash Kambadakone
NFNathan E. Frenk
Nathan E. Frenk
PMPeter R. Mueller
Peter R. Mueller
RARonald S. Arellano
Ronald S. Arellano

23 May 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AAAndrew S Allegretti
Andrew S Allegretti
NFNathan E Frenk
Nathan E Frenk
DLDarrick K Li
Darrick K Li
HSHarish Seethapathy
Harish Seethapathy
XPXavier F Vela Parada
Xavier F Vela Parada
KYKei Yamada
Kei Yamada
The MELD score was developed to predict survival after transjugular intrahepatic portosystemic shunt (TIPS) placement. Given changes in practice patterns and development of new prognostic tools in cirrhosis, we aimed to evaluate common models to predict mortality after TIPS placement. Analysis of consecutive patients who underwent TIPS placement for ascites or bleeding. Performance to predict 90-day mortality was assessed by C statistic for six models (MELD, MELD-Na, CLIF-C ACLF, Child-Pugh, Platelet-Albumin-Bilirubin, and Emory score). Added predictive value to MELD score was assessed for univariate predictors of 90-day mortality. Stratified analysis by TIPS indication, emergent placement status, and TIPS stent type was performed. 413 patients were analyzed (248 with variceal bleeding, 165 with refractory ascites). 90-day mortality was 27% (113/413). Mean MELD score was 15 ± 7.9. MELD score best predicted mortality for all patients (c = 0.779), for variceal bleeding (c = 0.844), and for emergent TIPS (c = 0.817). CLIF-C ACLF score best predicted mortality for refractory ascites (c = 0.707). Addition of sodium to the MELD score did not improve predictive value across multiple strata. Addition of hemoglobin improved MELD score’s predictive value in variceal bleeding. Addition of age improved MELD score’s predictive value in refractory ascites. MELD score best predicted 90-day mortality. Addition of sodium to the MELD score did not improve its performance, though mortality prediction was improved using Age-MELD for ascites and Hemoglobin-MELD for bleeding. An individualized risk stratification approach may be best when considering candidates for TIPS placement.

1 February 2022 in Radiology: Cardiothoracic Imaging
Verified
Journal Article
Closed access
SMShaunagh McDermott
Shaunagh McDermott
NFNathan E. Frenk
Nathan E. Frenk
FFFlorian J Fintelmann
Florian J Fintelmann
MPMelissa C. Price
Melissa C. Price
HOHarald C. Ott
Harald C. Ott
ASAmita Sharma
Amita Sharma
CT-guided fiducial marker placement was a safe and effective technique for localizing pulmonary nodules for preoperative planning. Purpose To assess the technical success and complication rates of CT-guided fiducial marker placement for the localization of pulmonary nodules and to assess the surgical localization failure rate....

1 January 2016 in Clinics
Verified
Journal Article
Open access
NFNathan Elie Frenk
Nathan Elie Frenk
FSFernando Sebastianes
Fernando Sebastianes
ALAntonio Marcondes Lerario
Antonio Marcondes Lerario
MFMaria Candida B. V. Fragoso
Maria Candida B. V. Fragoso
BMBerenice Bilharinho Mendonca
Berenice Bilharinho Mendonca
MMMarcos Roberto de Menezes
Marcos Roberto de Menezes
To evaluate the safety and long-term efficacy of computed tomography-guided percutaneous ethanol ablation for benign primary and secondary hyperfunctioning adrenal disorders. We retrospectively evaluated the long-term results of nine patients treated with computed tomography-guided percutaneous ethanol ablation: eight subjects who presented with primary adrenal disorders, such as pheochromocytoma, primary macronodular adrenal hyperplasia and aldosterone-producing adenoma, and one subject with Cushing disease refractory to conventional treatment. Eleven sessions were performed for the nine patients. The patient data were reviewed for the clinical outcome and procedure-related complications over ten years. Patients with aldosterone-producing adenoma had clinical improvement: symptoms recurred in one case 96 months after ethanol ablation, and the other patient was still in remission 110 months later. All patients with pheochromocytoma had clinical improvement but were eventually submitted to surgery for complete remission. No significant clinical improvement was seen in patients with hypercortisolism due to primary macronodular adrenal hyperplasia or Cushing disease. Major complications were seen in five of the eleven procedures and included cardiovascular instability and myocardial infarction. Minor complications attributed to sedation were seen in two patients. Computed tomography-guided ethanol ablation does not appear to be suitable for the long-term treatment of hyperfunctioning adrenal disorders and is not without risks.